<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01180283</url>
  </required_header>
  <id_info>
    <org_study_id>CRIST 002</org_study_id>
    <nct_id>NCT01180283</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Lodenafil Carbonate in the Treatment of Erectile Dysfunction in Patients With Diabetes.</brief_title>
  <official_title>Efficacy and Safety of Lodenafil Carbonate in the Treatment of Erectile Dysfunction in Patient With Type II Diabetes. Multicentric Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cristália Produtos Químicos Farmacêuticos Ltda.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cristália Produtos Químicos Farmacêuticos Ltda.</source>
  <brief_summary>
    <textblock>
      Sixty diabetes men with erectile dysfunction from mild to severe who agree to participate is&#xD;
      going to have medical care approximately for 16 weeks.&#xD;
&#xD;
      During the first 4 weeks, patients will not receive any inhibitor of phosphodiesterase 5. In&#xD;
      the following eight weeks, patients will receive oral lodenafil carbonate. They will complete&#xD;
      the International Index of Erectile Dysfunction (IIEF) questionnaire in the site and answer&#xD;
      the Sexual Encounter Profile (SEP) questions 2 and 3 and the Erection Hadness Score (EHS)&#xD;
      after each intercourse or attempt without or using oral lodenafil cardonate 80mg.&#xD;
&#xD;
      Questionnaire of adverse event is included in patient diary.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, fixed dose, open label study.&#xD;
&#xD;
      The run in period from inclusion to conclusion will be between fourteen and sixteen weeks.&#xD;
&#xD;
      Visit zero (Vo):&#xD;
&#xD;
        -  Patients will sign the informed consent form;&#xD;
&#xD;
        -  Investigator will clinically evaluate the subjects regarding eligibility criteria;&#xD;
&#xD;
        -  Safety laboratory tests will be perform ;&#xD;
&#xD;
        -  Patients will answer the erectile function domain of the International Index of Erectile&#xD;
           Function (IIEF);&#xD;
&#xD;
      Study coordinator:&#xD;
&#xD;
      Will orientate subjects regarding the follow:&#xD;
&#xD;
        -  Patients will not use any phosphodiesterase- 5 inhibitor (iPDE-5) for four weeks;&#xD;
&#xD;
        -  When intercourse or attempt happen, subjects will fill a diary;&#xD;
&#xD;
      Patients' diary includes: questions 2 and 3 of Sexual Encounter Profile (SEP), the Erectile&#xD;
      Hardness Score (EHS) and adverse events data.&#xD;
&#xD;
      Subject will return after four weeks.&#xD;
&#xD;
      Visit One (V1):&#xD;
&#xD;
        -  Patients will answer basal IIEF;&#xD;
&#xD;
        -  Investigator will inform to patient the laboratory tests results;&#xD;
&#xD;
      Study coordinator:&#xD;
&#xD;
        -  Will give to the patients eight pills of lodenafil carbonate;&#xD;
&#xD;
        -  Will give instructions about study medication; Patient should take one pill from six to&#xD;
           two hours before intercourse or attempt, with or without food intake or drink. The&#xD;
           patient will not take more than one pill daily.&#xD;
&#xD;
        -  When intercourse or attempt happen, subjects will fill out the diary; Patients' diary&#xD;
           includes: questions 2 and 3 of Sexual Encounter Profile (SEP), the Erectile Hardness&#xD;
           Score (EHS) and adverse events data.&#xD;
&#xD;
      Subject will return after four weeks.&#xD;
&#xD;
      Visit two (V2)&#xD;
&#xD;
      Study coordinator:&#xD;
&#xD;
        -  Will give to patient eight pills of lodenafil carbonate;&#xD;
&#xD;
        -  Will give instructions about study medication:&#xD;
&#xD;
      Patient will take one pill from six to two hours before intercourse or attempt, with or&#xD;
      without food intake or drink. The patient will not take more than one pill daily.&#xD;
&#xD;
      - When intercourse or attempt happen, subjects will fill out the diary;&#xD;
&#xD;
      Patients' diary includes: questions 2 and 3 of Sexual Encounter Profile (SEP), the Erectile&#xD;
      Hardness Score (EHS) and adverse events data.&#xD;
&#xD;
      Subject will return after four weeks.&#xD;
&#xD;
      Visit three (V3)&#xD;
&#xD;
        -  Patients will answer the International Index of Erectile Function (IIEF);&#xD;
&#xD;
        -  Safety laboratory will be perform ;&#xD;
&#xD;
      Visit four (V4)&#xD;
&#xD;
      - Investigator will inform to patients the laboratory tests results;&#xD;
&#xD;
      Complete medical evaluation including adverse event questions and physical examinations will&#xD;
      be done at all visits.&#xD;
&#xD;
      Efficacy will be assessed by files of patients who complete the study and did not have&#xD;
      protocol violation (per protocol population).&#xD;
&#xD;
      Main outcomes to measure efficacy: IIEF (questions 1 to 15), SEP question 2 (Were you able to&#xD;
      insert your penis into your partner's vagina?), SEP question 3 (Did your erection last long&#xD;
      enough for you to have successful intercourse?), EHS (Erection Hardness Score).&#xD;
&#xD;
      Tolerability will be assessed by files of patients intend to treat - subjects who took the&#xD;
      study medication at least once.&#xD;
&#xD;
      Patients logs contain questions such as: Did you experience any uncomfortable symptoms?; At&#xD;
      what time this symptoms began?; Did you take medication to relieve the symptoms?; Did you go&#xD;
      to the hospital /or doctor's office?.&#xD;
&#xD;
      After review the logs, investigator will interview patients to fill adverse events reports.&#xD;
      Investigator will assess the event intensity (from mild to severe) and will define the casual&#xD;
      relationship to the study medication (definite; probable; possible; doubtful).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date>April 2010</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evidence that lodenafil carbonate improves erectile function in patients with diabetes type 2.</measure>
    <time_frame>16 mounths</time_frame>
    <description>Efficacy is assessing by files of patients including questionnaires like IIEF, SEP and EHS.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events in type 2 diabetes patients taking lodenafil carbonate and laboratory tests changes after this treatment.</measure>
    <time_frame>16 months</time_frame>
    <description>Investigator will interview patients to fill adverse events reports.&#xD;
Laboratory tests results before and after lodenafil carbonate treatment will be analyzed and compared, in order to detect significant changes.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <condition>Erectile Dysfunction</condition>
  <arm_group>
    <arm_group_label>lodenafil carbonate (Helleva®)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lodenafil carbonate</intervention_name>
    <description>Dosage: lodenafil carbonate 80mg once a day. It should be taken between 6 and 2 hours before the sexual intercounter.</description>
    <arm_group_label>lodenafil carbonate (Helleva®)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diabetes type II;&#xD;
&#xD;
          -  Age from 18 to 65 years;&#xD;
&#xD;
          -  Erectile dysfunction within the previous 6 months;&#xD;
&#xD;
          -  Mild, moderate or severe erectile dysfunction by IIEF questionnaire;&#xD;
&#xD;
          -  Stable sexual partner in the past 2 months;&#xD;
&#xD;
          -  Preserved libido;&#xD;
&#xD;
          -  Studied at least up to fourth grade;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current beta blocker, thiazide, alpha methyldopa, antidepressants, or antiandrogen&#xD;
             therapy intake;&#xD;
&#xD;
          -  Penile prosthesis;&#xD;
&#xD;
          -  Previous intolerance to sildenafil, vardenafil, tadalafil or lodenafil carbonate;&#xD;
&#xD;
          -  Previous negative response to iPDE-5 correct use.;&#xD;
&#xD;
          -  Penile anatomical deformities;&#xD;
&#xD;
          -  Previous penile surgeries for erectile dysfunction, premature ejaculation or penile&#xD;
             enlargement;&#xD;
&#xD;
          -  Myocardial infarction or cerebral vascular accident within the previous 6 months;&#xD;
&#xD;
          -  Severe or uncontrolled cardiac diseases;&#xD;
&#xD;
          -  Spinal cord injury, multiple sclerosis, retinitis pigmentosa;&#xD;
&#xD;
          -  Radical pelvic surgery and pelvic radiotherapy, including radical prostatectomy;&#xD;
&#xD;
          -  Myocardial or Coronary Artery disease with cardiologist contraindication for using&#xD;
             iPDE5;&#xD;
&#xD;
          -  Cancer;&#xD;
&#xD;
          -  Anaphylactic reactions or Steven-Johnson disease;&#xD;
&#xD;
          -  Participation in another clinical trial within the last 2 months;&#xD;
&#xD;
          -  Sexually transmitted diseases;&#xD;
&#xD;
          -  Glycated hemoglobin &gt; 12%;&#xD;
&#xD;
          -  Testosterone &lt; 200ng/dL;&#xD;
&#xD;
          -  Prolactin &gt; 20ng/dL;&#xD;
&#xD;
          -  Hemoglobin &lt; 10g/dL;&#xD;
&#xD;
          -  Leucocytes &gt; 14.000 cel/mm3;&#xD;
&#xD;
          -  TGO &gt; 100 U/L;&#xD;
&#xD;
          -  TGP &gt; 100 U/L;&#xD;
&#xD;
          -  Creatina &gt; 2 mg/dL;&#xD;
&#xD;
          -  Investigator´s opinion;&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital do Servidor Público Estadual de São Paulo</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <zip>04039-004</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Faculdade de Medicina do ABC</name>
      <address>
        <city>Santo André</city>
        <state>São Paulo</state>
        <zip>09060-650</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Ipiranga</name>
      <address>
        <city>São Paulo</city>
        <zip>04262-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>August 2010</verification_date>
  <study_first_submitted>July 29, 2010</study_first_submitted>
  <study_first_submitted_qc>August 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 12, 2010</study_first_posted>
  <last_update_submitted>August 10, 2010</last_update_submitted>
  <last_update_submitted_qc>August 10, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 12, 2010</last_update_posted>
  <responsible_party>
    <name_title>Jorge Barros Afiune</name_title>
    <organization>CRISTÁLIA PRODUTOS QUÍMICOS FARMACÊUTICOS LTDA</organization>
  </responsible_party>
  <keyword>Erectile dysfunction</keyword>
  <keyword>Lodenafil carbonate</keyword>
  <keyword>Diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erectile Dysfunction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

